Restart Life Sciences Corp.
NMLSF
$0.06
$0.02887.50%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -198.58% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -198.58% | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -198.58% | -- | -- | -- |
| SG&A Expenses | -45.98% | -59.99% | -58.65% | -50.31% | -37.09% |
| Depreciation & Amortization | -20.00% | -22.73% | -25.00% | -26.92% | -28.57% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -49.08% | -61.95% | -61.50% | -51.67% | -37.30% |
| Operating Income | 49.06% | 59.09% | 61.53% | 51.71% | 37.33% |
| Income Before Tax | 118.05% | 100.62% | 72.87% | 64.85% | 51.72% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 118.05% | 100.62% | 72.87% | 64.85% | 51.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 118.05% | 100.62% | 72.87% | 64.85% | 51.72% |
| EBIT | 49.06% | 59.09% | 61.53% | 51.71% | 37.33% |
| EBITDA | 49.12% | 59.19% | 61.61% | 51.76% | 37.35% |
| EPS Basic | 117.77% | 100.47% | 73.51% | 65.83% | 55.40% |
| Normalized Basic EPS | 51.16% | 58.77% | 60.80% | 50.19% | 37.88% |
| EPS Diluted | 96.37% | 89.56% | 65.26% | 57.92% | 48.34% |
| Normalized Diluted EPS | 53.75% | 59.24% | 60.80% | 50.19% | 37.88% |
| Average Basic Shares Outstanding | 4.11% | 1.51% | 2.16% | 2.84% | 7.52% |
| Average Diluted Shares Outstanding | 8.06% | 2.35% | 2.16% | 2.84% | 7.52% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |